Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report

Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report

IntroductionClozapine and chlorpromazine are widely used for treating schizophrenia. However, irregular medical follow-ups are common in patients with schizophrenia, potentially leading to long-term super-dose medication. Managing such cases poses significant challenges for clinical psychiatrists.Ca...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaobo Xie, Jinzhang Chen, Hongli Song, Zebin Fan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Psychiatry
Subjects:	clozapine chlorpromazine antipsychotics schizophrenia case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1533350/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
by: Jari Tiihonen, et al.
Published: (2012-01-01)

Antipsychotic and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophreniaResearch in context
by: Siobhan K. Lock, et al.
Published: (2025-06-01)

Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report
by: Salvatore Cipolla, et al.
Published: (2025-03-01)

Reduced SARS-CoV-2 vaccine-specific antibody response associated with high clozapine doses in schizophrenia spectrum disorders
by: Itziar Montalvo, et al.
Published: (2025-07-01)

A cross-sectional study to analyze the pattern of pharmacotherapy and its associated factors among patients with schizophrenia
by: B. S. Abhishree, et al.
Published: (2024-12-01)

Olanzapine-induced Pancytopenia: Case Report
by: A Prajnashree, et al.
Published: (2024-11-01)

Study of factors associated with obesity in patients using antipsychotics in schizophrenia
by: Vishalakshi Patnam, et al.
Published: (2024-12-01)

Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia
by: A. R. Asadullin, et al.
Published: (2025-06-01)

The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

COVID-19 disease outcomes in patients receiving clozapine versus other antipsychotics: a national study in Qatar
by: Dalia Albahari, et al.
Published: (2025-05-01)

The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China
by: Huaning Wang, et al.
Published: (2025-07-01)

Pattern of Antipsychotics in Schizophrenia Outpatients at Lampung Province Mental Hospital
by: Isnenia Isnenia
Published: (2022-03-01)

Correction: The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
by: Leonid Mikhaylovich Bardenshteyn, et al.
Published: (2010-06-01)

Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia
by: Mulualem Kelebie, et al.
Published: (2025-02-01)

A case of clozapine-induced stuttering in a HIV-positive individual
by: Paidamoyo F. Kambuzuma, et al.
Published: (2025-07-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Manipulation of Lipid Nanocapsules as an Efficient Intranasal Platform for Brain Deposition of Clozapine as an Antipsychotic Drug
by: Ahmed A. Katamesh, et al.
Published: (2024-11-01)

The Prevalence of Tardive Dyskinesia In Patients With Schizophrenia Treated With Antipsychotics In Malaysia
by: Nedunjelian A, et al.
Published: (2025-03-01)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
by: Ye. G. Kornetova, et al.
Published: (2015-02-01)

Clozapine-induced hypertension: A paradox
by: Hamza Hussain, et al.
Published: (2024-12-01)

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
by: Dhandapani Nandakumar, et al.
Published: (2023-06-01)

Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
by: S. A. Galkin, et al.
Published: (2024-04-01)

Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysisResearch in context
by: Myrto Samara, et al.
Published: (2025-06-01)

Combined use of antipsychotics and electroconvulsive therapy in theurapetically resistant schizophrenia
by: S. V. Sizov, et al.
Published: (2018-07-01)

Guideline for the use of therapeutic drug monitoring of antipsychotics to individualize the selection of therapy in the treatment of exacerbation of schizophrenia
by: S. S. Potanin, et al.
Published: (2023-12-01)

Intranasal delivery of blackberry-loaded Chitosan nanoparticles for antipsychotic potential in Ketamine-induced schizophrenia in rats
by: Mina Y. George, et al.
Published: (2025-05-01)

Association of neutrophil-to-lymphocyte ratio with antipsychotic administration in schizophrenia: A longitudinal study
by: Rajnish Raj, et al.
Published: (2025-01-01)

The effect of clozapine on immune-related biomarkers in schizophrenia patients
by: Lu Shao, et al.
Published: (2024-11-01)

Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients
by: Takashi Kusunoki, et al.
Published: (2025-05-01)

Sustained long-term improvement with clozapine in schizophrenia Clozapina na esquizofrenia grave: melhora duradoura e sustentada
by: RICARDO DE OLIVEIRA-SOUZA, et al.
Published: (1999-03-01)

Effective and underprescribed: what about clozapine?
by: Helge H.O. Müller
Published: (2017-10-01)

Clozapine and tuberculosis treatment: a case report and literature review
by: Neel Swamy, et al.
Published: (2025-07-01)

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
by: A. A. Goncharova, et al.
Published: (2020-01-01)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
by: de Bartolomeis A, et al.
Published: (2016-01-01)

Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
by: Anna-Theresa Schulze, et al.

Haloperidol versus second-generation antipsychotics on the cognitive performance of individuals with schizophrenia and related disorders: pairwise meta-analysis of randomized controlled trials
by: Daniel Prates Baldez, et al.
Published: (2025-05-01)